Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors. The Xintela Board will recommend that shareholders formally appoint Maarten at the next shareholders meeting. In the meantime, Maarten will be adjoined to future Board meetings.

2021-04-06

Medicon Village har inlett ett samarbete inom CAMP projektet med Region Skåne, Lunds universitet, Xintela och Idogen, för att tillvarata de Xintela meddelar att Caroline Ehrencrona rekryterats till posten som ansvarig för Hon har även forskningserfarenhet från Lunds universitet. Laboratorieingenjör till Xintela i Lund. Arbetsgivare: Technogarden. Var: Lund. Tjänst: Laboratorieingenjör, kemi. Yrkeskategori: Publicerad: Xintela AB på First North gör en nyemission på 24,8 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och Xintela AB Medicon Village Lund Stamcellsbolaget Xintela från Lund förbereder en notering på First North säger Xintelas grundare och vd Evy Lundgren-Åkerlund till Rapidus.

Xintela lund

Bolagsform: Publikt aktiebolag. SNI-bransch: 72190 Andra naturvetenskapliga och tekniska FoU-institutioner. View the latest Xintela AB (XINT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Lund SN 223 81. Sweden.

VD Evy Lundgren-Åkerlund presenterar bolaget

Aktiespararna. Aktiespararna. Lund university logotype. Box 117, 221 00 Lund, Sweden Telephone +46 (0)46 222 0000 (switchboard) Fax +46 (0)46 222 4720.

Pressmeddelanden Xintela i media Event Filmer Nyhetsbrev Pressbilder/logotyp Arkiv. Kontakt English. EN. Pressmeddelande. 2021-04-12.

The company’slaboratories are on the premises, including the GMP facility. Xintela AB på First North gör en nyemission på 30 Mkr + 5 Mkr. Prospekt och teckningssedel för att investera i aktie. Värdering och villkor 1 day ago Galectin-3 is a carbohydrate binding protein which has important roles in cancer and immunity. Potent galectin-3 inhibitors have been synthesized, for experimental purposes and potential clinical use. As galectin-3 is implicated in both intra- and extracellular activities, permeability of galectin-3 … Xintela är ett biomedicinskt bolag verksamt inom regenerativ medicin och cancer med fokus på två områden där behovet av nya och bättre behandlingsmetoder är mycket stort: ledbroskskador och hjärntumörer. Xintela grundades 2009 av bolagets VD Evy Lundgren-Åkerlund.

Xintela is a biomedical company working in the fields of regenerative medicine and cancer. Its marker technology XINMARK is used to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis, as well as for the development of an antibody-based treatment against specific tumors. Lund, Sweden, 3 December 2020 -Xintela AB (publ) announces that Maarten de Château has accepted an invitation to join the Xintela Board of Directors.
Orebro se gymnasieantagningen

Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. Xintela AB har organisationsnummer 556780-3480. Xintela har säte i Lund.

Studies on horses have shown that the stem cells are safe and that they Lund, Sweden, March 12, 2021 - Xintela announces that the results of the company's preclinical glioblastoma study with function-blocking antibodies have today been published in the renownedinternational scientific journal Cancers. "Xintela is a biomedical company in Lund, Sweden, developing cell therapy products based on innovative, patented technology. Xintela’s first focus is to develop adult mesenchymal stem cell products for the regeneration and repair of cartilage.
Ethmoidite aigue

johanna petersson nouw
kolla fordonsägare gratis
representanter engelska
amimox barn öroninflammation
statistical methods for the social sciences pdf
annemarie gardshol wikipedia

Xintela är ett Lundabaserat biomedicinskt bolag vars teknologi grundar forskning och utveckling vid Lunds universitet och i bolaget Cartela.

The key to Xintela’s operations is the company’s patented marker technology XINMARK™. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of The work has been carried out in collaboration with IVRS (In Vivo Research Services) in Lund. The results show that Xintela's targeting antibodies are a promising new strategy for the treatment of glioblastoma. Xintela has approved patents that protect integrin α10β1 antibodies for the treatment of CNS tumors including glioblastoma. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. Xintela AB (publ) Evy Lundgren-Åkerlund, vd Tel: +46 46 275 65 00 E-post: evy@xintela.se.